NCODA shared a post on LinkedIn:
“The BREAKWATER trial found that adding encorafenib + cetuximab to mFOLFOX6 improved survival versus standard first-line therapy in BRAF V600E–mutated metastatic colorectal cancer.
NCODA’s Positive Quality Intervention resource helps care teams put this regimen into practice safely, efficiently, and consistently, by providing:
- Clear dosing and infusion schedules for each drug in the regimen
- Pre-medication and antiemetic strategies to help patients avoid early toxicity
- Lab and ECG monitoring recommendations to catch issues before they escalate
- Supportive care approaches for rash, neuropathy, and GI side effects
- Access and assistance programs to reduce financial barriers
These practical, ready-to-use steps help ensure the benefits proven in the trial reach patients in everyday oncology care.
More posts featuring NCODA.